Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Q4 2022 Earnings Call Transcript

And so, a lot of that it will, again, will depend on where we think the FDA will want us to go, where the market is for this drug in terms of type of pancreatic cancer, or in terms of what stage of pancreatic cancer, or surgical/nonsurgical. So there’s always nuances of pancreatic cancer that we have to discuss with the FDA and then evaluate from a market as well as drug development timeframe, as well as costs, which is about to go.

Naz Rahman : Got it. Thanks for taking all my questions.

David Young : Thanks, Naz.

Operator: Okay. We have no further questions in queue. We have reached the end of the question-and-answer session. This concludes today’s conference, and you may disconnect your lines at this time. Thank you for your participation.

David Young : Thank you.